Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925170 · ClinicalTrials.gov registry record · NA
Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 1,638
- Enrollment target
NCT01925170: Completed NA study, sponsored by Mayo Clinic.
NCT01925170 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 1,638 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01925170, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,638 participants
- Enrollment target
Study Summary
A new test for breast cancer screening, molecular breast imaging (MBI) may be more sensitive than mammography for detecting breast cancer in women with dense breasts. The purpose of this study is to see if MBI using a low dose of gamma radiation can find cancers not seen on mammography. Hypotheses: 1. Low-Dose MBI has a significantly higher sensitivity and specificity and equal or higher positive predictive value than SM in women age 40 and older with mammographically dense breasts. 2. Low-dose MBI has comparable sensitivity and specificity to that previously achieved with MBI using a higher dose of radiation. 3. MBI produces a low false positive rate (specificity \>90%) that permits its use as a screening tool in this patient population.
Interventions
- DEVICE Molecular Breast Imaging
- DEVICE Conventional Mammography
- DRUG Technetium (99mTc) sestamibi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,638 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925170
The ClinicalTrials.gov registry entry for NCT01925170 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,638 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Molecular Breast Imaging is the first listed.
NCT01925170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01925170 about?
NCT01925170 is a clinical study titled "Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts". A new test for breast cancer screening, molecular breast imaging (MBI) may be more sensitive than mammography for detecting breast cancer in women with dense breasts. The purpose of this study is to see if MBI using a low dose of gamma radiation can find cancers not seen on mammography. Hypotheses:...
What is the current status of trial NCT01925170?
This trial is currently completed. It is a NA study. The enrollment target is 1,638 participants. The study started on 2009-04. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01925170?
The interventions under investigation include: Molecular Breast Imaging (DEVICE), Conventional Mammography (DEVICE), Technetium (99mTc) sestamibi (DRUG).
Who is sponsoring clinical trial NCT01925170?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.